Baird Financial Group
PCVX icon

Baird Financial Group’s Vaxcyte PCVX Stock Holding History

Baird Financial Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$803K Buy
13,813
+25
+0.2% +$1.36K ﹤0.01% 1398
2026
Q1 		$801K Hold
13,788
– – ﹤0.01% 1331
2025
Q4 		$636K Sell
13,788
-929
-6% -$41.5K ﹤0.01% 1393
2025
Q3 		$530K Buy
14,717
+418
+3% +$13.8K ﹤0.01% 1447
2025
Q2 		$465K Hold
14,299
– – ﹤0.01% 1439
2025
Q1 		$540K Buy
14,299
+2,523
+21% +$202K ﹤0.01% 1371
2024
Q4 		$964K Sell
11,776
-2,341
-17% -$232K ﹤0.01% 1191
2024
Q3 		$1.61M Sell
14,117
-5,016
-26% -$452K ﹤0.01% 1027
2024
Q2 		$1.44M Buy
19,133
+2,660
+16% +$181K ﹤0.01% 1053
2024
Q1 		$1.13M Sell
16,473
-26,984
-62% -$1.87M ﹤0.01% 1128
2023
Q4 		$2.73M Buy
+43,457
New +$2.26M 0.01% 849

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Baird Financial Group's PCVX Position: Q2 2026 in Review

Baird Financial Group increased its Vaxcyte (PCVX) stake by 0.18% in Q2 2026, buying an estimated $1.36K and bringing the position to 13,813 shares worth $803K. The position accounts for ﹤0.01% of the portfolio, ranked #1398.

Baird Financial Group first reported a position in PCVX in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.73M in Q4 2023. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Baird Financial Group held 13,813 shares of Vaxcyte worth $803K as of Q2 2026.
  • Baird Financial Group bought 25 Vaxcyte shares in Q2 2026, an estimated $1.36K.
  • Vaxcyte made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1398 holding.
  • Baird Financial Group first reported a position in Vaxcyte in Q4 2023 and has held it in 11 quarters since.
  • Baird Financial Group's Vaxcyte position peaked at $2.73M in Q4 2023.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.